Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

OncoZenge Appoints Anna Asplind as Phase 3 Program Manager

Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager.As previously communicated the OncoZenge strategy and focus is planning for a pivotal phase 3-program towards European market authorization of BupiZenge™, together with a partner. The company is still evaluating the best partner options and plans but is pleased to confirm the appointment of Anna Asplind as Phase 3 Program Manager in support of OncoZenge’s

ANNUAL REPORT 2023 ZINZINO AB (PUBL)

Zinzino (publ) announces that the company's annual report for 2023 in Swedish is now published on the company's website, zinzino.com.  The English version will be published within approximately 45 days. The 2024 Annual General Meeting will be held at the company's premises at Hulda Mellgrens gata 5 in Västra Frölunda on May 27 at 1:30 p.m. The nomination committee's proposals for board members, the board's remuneration and auditors are presented in the notice to the annual general meeting. For further information about the annual general meeting, refer to the company's website www.

Transfer of own shares as a directed share issue based on share-based incentive plan

Neste Corporation, Stock Exchange Release, 26 April 2024 at 3.00 p.m. (EET)Neste Corporation has on 26 April 2024 transferred 2 201 treasury shares to a key person participating in the Performance Share Plan 2021-2023 and Restricted Share Plans 2021-2023 and 2022-2024 of Neste Corporation. The shares were transferred as a share reward without consideration in accordance with the terms and conditions of the plans. The plans are part of the share-based incentive scheme 2019 of Neste, announced with a stock exchange release on 11 December 2018 and part of the share-based incentive scheme

Bulletin from Kindred Group plc’s Annual General Meeting

At Kindred Group plc’s (“Kindred”) annual general meeting held on 26 April 2024 (the “AGM”) 35.01 per cent in nominal value of the total shares/Swedish depository receipts (“SDRs”) in issue were represented. At the AGM, Evert Carlsson, James H. Gemmel, Heidi Skogster, Cédric Boireau, Jonas Jansson, Andy McCue, Martin Randel and Kenneth Shea were re-elected as Directors of the Company. In addition, Evert Carlsson was re-appointed as the Chairman of the Board. In addition, at the AGM, the resolution to pay a total fee of GBP 806,500 to Directors elected at the AGM, who are not employed

Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A

Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.   Efanesoctocog alfa provides children, adolescents and adults with normal to near-normal factor VIII activity levels (above 40%) for a significant part of the week with once-

Eevia Health Plc receives a 590 kSEK (51 kEUR) repeat sales order

Eevia Health Plc, (”Eevia” or ”The Company”), has received a 51 kEUR sales order from a European nutraceutical brand owner with delivery in June 2024 of a bilberry extract.The customer is a European brand owner headquartered in Sweden. The customer develops and markets effective herbal dietary supplements, as well as cosmetics in over 50.000 pharmacies, health food shops, and other retail outlets across 36 countries, including China and USA. The purchase order is a repeat order with a sales value to Eevia of c. 51 kEUR for delivery in June. Eevia has the product in stock and can

Vasakronan’s interim report January–March 2024

Stable income from property management· Rental revenue increased 5% to a total of SEK 2,338 million (2,221). The increase was primarily due to indexation. In comparable property holdings, the increase in rental revenue was 5%. · New lettings corresponding to 28,000 square metres (23,000) and annual rent of SEK 180 million (121) were contracted. Net lettings amounted to negative SEK 25 (negative: 46). · The occupancy rate was 90.1% at the end of the period and was 90.9% at the end of 2023. · Operating surplus increased 8% to a total of SEK 1,751 million (1,620). For comparable

Railway Metrics and Dynamics AB has entered into a collaboration agreement with AB Transitio

Railway Metrics and Dynamics AB (RMD) has today signed a collaboration agreement with AB Transitio as part of the Swedish Transport Administration's innovation procurement "Measurement of Infrastructure from Railway Vehicles" (MAJ).Read more: Million-dollar agreement signed with the Swedish Transport Administration Read more: Swedish Transport Administration activates Stage 2 in contract with Railway Metrics and Dynamics 

Immedica announces publication of 2023 Business Review and Annual & Sustainability Report

Stockholm, April 26, 2024 – Immedica is proud to announce the release of our Business Review and Annual & Sustainability Report for the year 2023. This year marks the most successful period in our history since the company's establishment in 2018, highlighting our substantial progress and achievements. In 2023, Immedica strengthened its position as an emerging leader in the rare disease sector across Europe and the MENA region. Through strategic initiatives and a dedicated focus on our core mission, we have taken significant strides toward becoming a frontrunner in this important field.

Cell Impact signs agreement valued at 3.2 million SEK

A leading Japanese, global supplier has placed an order with F.C.C., encompassing design, tools, and prototypes, which Cell Impact AB (publ) will deliver.The order is a direct result of the elaborated collaboration between Cell Impact AB (publ) and Japanese company F.C.C. Co., Ltd., which commenced with the installation of a demonstration line at F.C.C.’s facility in late 2022. “The company that placed the order was one of the companies that evaluated Cell Impact Forming™, our unique and patented forming technology, at F.C.C. The order includes the design of tools and flow plates, as

Electrolux Professional Group acquires Adventys – a specialist in Induction technology

Electrolux Professional Group has today acquired Adventys – a French manufacturer of induction cooking solutions.“Induction cooking significantly reduces CO2 emissions compared to other technologies such as gas since it only uses energy when the surface is activated, which makes it the technology for the future of sustainable cooking. With the acquisition of Adventys we will be able to gain access to the development of our own induction technology while we at the same time are maintaining and strengthening our leadership in horizontal cooking,” says Alberto Zanata, President and CEO of

BioStock: Medivir optimizes study design after meeting FDA

Medivir has held another meeting with the FDA concerning the upcoming global phase IIb study, in which the company’s drug candidate, fostrox, will be evaluated in combination with Lenvima in liver cancer patients. The aim is to initiate the study in the US by early 2025.– We have great momentum in the development program with fostrox right now, says Medivir’s CEO Jens Lindberg.Read the full interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2024/04/medivir-optimizes-study-design-after-meeting-fda/ This is a press release from BioStock - Connecting Innovation &

Esmaeilzadeh Holding publishes annual report and sustainability report for 2023

"We continue to promote EHAB's financial stability and value creation, with the ambition of making EHAB debt-free in 2024. At the same time, we actively support our portfolio companies to strengthen their business development and increase the portfolio's resilience. We are confident that these initiatives are well in line with our long-term strategy." - Mikael Ericson, Chief Executive Officer Financial overview · Total net asset value was MSEK 7,164 (7,607), equivalent to SEK 9,294 per share (9,869). · Total assets were MSEK 8,751 (8,817). · Net cash/debt amounted to MSEK -1,

Shape Robotics secures Smartlab-order worth 30 Mio. Euro from NOD

Todays order from NOD for an additional 900 Smartlabs is a direct result of the grants awarded to over 1400 schools in Romania through the EU Recovery and Resilience Plan, ensuring full funding. This order commences with an immediate delivery of 100 Smartlabs, followed by a steady supply of 50 Smartlabs weekly throughout 2024. This brings the total to 900 laboratories, culminating in an approximate value of 30 million euros. This development not only fulfills ShaPe Robotics existing framework agreement with NOD but also sets the stage for a proposed expansion of the contract by a minimum

Kesko Corporation: Disclosure in compliance with Chapter 9, Section 10 of the Finnish Securities Markets Act (24.4.2024)

Kesko Corporation has on 25 April 2024 received a notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act from BlackRock, Inc. According to the notification, on 24 April 2024, BlackRock, Inc.’s holding in Kesko Corporation, including holding through financial instruments, fell below the threshold of five (5) per cent of shares. According to the notification of BlackRock, Inc.: % of % of shares Total of Total number of shares shares and voting both in % and voting rights of and

Kesko Oyj - Managers' Transactions (Timo Ritakallio)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Timo RitakallioPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59956/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 887 Unit price: 0 EURAggregated

Kesko Oyj - Managers' Transactions (Jussi Perälä)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Jussi PeräläPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59955/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 887 Unit price: 0 EURAggregated transactions (

Kesko Oyj - Managers' Transactions (Piia Karhu)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Piia KarhuPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59946/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 887 Unit price: 0 EURAggregated transactions (1):

Kesko Oyj - Managers' Transactions (Pauli Jaakola)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Pauli JaakolaPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59941/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 887 Unit price: 0 EURAggregated transactions (

Kesko Oyj - Managers' Transactions (Jannica Fagerholm)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Jannica FagerholmPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59937/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 1171 Unit price: 0 EURAggregated

Kesko Oyj - Managers' Transactions (Peter Fagernäs)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Peter FagernäsPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59935/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 1171 Unit price: 0 EURAggregated

Kesko Oyj - Managers' Transactions (Esa Kiiskinen)

Kesko Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Esa KiiskinenPosition: Member of the Board/Deputy memberIssuer: Kesko OyjLEI: 743700OX6HSVMCAHPB95Notification type: INITIAL NOTIFICATIONReference number: 59920/5/4____________________________________________Transaction date: 2024-04-26Outside a trading venueInstrument type: SHAREISIN: FI0009000202Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 1899 Unit price: 0 EURAggregated transactions

Financial Report January - March 2024

Stockholm, Sweden, April 26, 2024(NYSE: ALV and SSE: ALIV.sdb) Q1 2024: Broad based improvements Financial highlights Q1 2024$2,615 million net sales5% net sales increase5% organic sales growth*7.4% operating margin7.6% adjusted operating margin*$1.52 EPS, 77% increase$1.58 adjusted EPS*, 76% increase Full year 2024 guidanceAround 5% organic sales growthAround 0% FX effect on net salesAround 10.5% adjusted operating marginAround $1.2 billion operating cash flowAll change figures in this release compare to the same period of the previous year except when

There are no items matching the current filter
There are no more items matching the current filter
Back to top